Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7820909 | 0.98 | ALDH1A1 (0.65) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3066454 | 0.94 | L3MBTL1 (0.61) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30674530 | 0.94 | L3MBTL1 (0.61) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29742239 | 0.89 | L3MBTL1 (0.77) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15380425 | 0.89 | KDM4E (0.50) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL30674616 | 0.88 | L3MBTL1 (0.58) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3528579 | 0.88 | L3MBTL1 (0.58) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29742293 | 0.85 | L3MBTL1 (0.70) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7819615 | 0.83 | SMN1; SMN2 (0.58) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL17911627 | 0.83 | KDM4E (0.52) | L3MBTL1TDP1ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| EP-0842174-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PF MEDICAMENT (FR) | 2001-10-04 | — | — | EP | disclosed |
| US-6011032-A | Heterocyclic compounds for treating myocardial ischemia | PIERRE FABRE MEDICAMENT (FR) | 2000-01-04 | — | — | US | disclosed |
| EP-0842174-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997005134-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | L3MBTL1 4797/4885TDP1 3607/4885ALDH1A1 142/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | L3MBTL1 4797/4885TDP1 3607/4885ALDH1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.